Handelsbanken Fonder Ab Myovant Sciences Ltd. Transaction History

Handelsbanken Fonder Ab

  • $25.3 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 07, 2023
BUY
$24.03 - $27.02 $185,031 - $208,054
7,700 New
7,700 $208,000
Q1 2021

Apr 29, 2021
SELL
$20.46 - $25.18 $229,152 - $282,016
-11,200 Closed
0 $0
Q4 2020

Feb 11, 2021
BUY
$13.8 - $27.62 $154,560 - $309,344
11,200 New
11,200 $309,000

Others Institutions Holding MYOV

# of Institutions
6
Shares Held
61.3K
Call Options Held
0
Put Options Held
0
View Full List

About Myovant Sciences Ltd.

MYOV Quotes by TradingView
  • Ticker MYOV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 96,802,800
  • Description
  • Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...
More about MYOV
Track This Portfolio

Track Handelsbanken Fonder Ab Portfolio

Follow Handelsbanken Fonder Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

News

Stay updated on Handelsbanken Fonder Ab with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email